Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
Dec 04
U.S. Life Sciences Industry Analysis
UpdatedDec 04, 2023
DataAggregated Company Financials
Companies77
- 7D1.4%
- 3M-11.1%
- 1Y-13.3%
- YTD-9.7%
In the last week, the Life Sciences industry is up 1.4%, with Danaher leading the way with a 1.6% gain. In the same time, Fortrea Holdings was down 7.2%. However, the industry is down 13% over the past year. Earnings are forecast to grow by 15% annually.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 04 Dec 2023 | US$651.8b | US$153.8b | US$14.0b | 35.5x | 46.5x | 4.2x |
| Wed, 01 Nov 2023 | US$572.6b | US$153.7b | US$11.2b | 29.7x | 51.3x | 3.7x |
| Fri, 29 Sep 2023 | US$670.3b | US$154.6b | US$11.2b | 33.1x | 59.8x | 4.3x |
| Sun, 27 Aug 2023 | US$712.7b | US$154.6b | US$11.2b | 32.9x | 63.6x | 4.6x |
| Tue, 25 Jul 2023 | US$744.7b | US$155.5b | US$12.7b | 29.5x | 58.7x | 4.8x |
| Thu, 22 Jun 2023 | US$691.0b | US$152.4b | US$12.5b | 29.2x | 55.3x | 4.5x |
| Sat, 20 May 2023 | US$683.0b | US$152.1b | US$12.5b | 29x | 54.8x | 4.5x |
| Mon, 17 Apr 2023 | US$737.3b | US$154.6b | US$10.8b | 30.5x | 68.2x | 4.8x |
| Wed, 15 Mar 2023 | US$711.8b | US$154.5b | US$10.9b | 30.4x | 65.5x | 4.6x |
| Fri, 10 Feb 2023 | US$743.6b | US$155.6b | US$8.8b | 30.9x | 84.1x | 4.8x |
| Sun, 08 Jan 2023 | US$705.6b | US$155.2b | US$8.8b | 27.6x | 80.4x | 4.5x |
| Tue, 06 Dec 2022 | US$765.6b | US$155.1b | US$8.8b | 28.2x | 87.3x | 4.9x |
| Thu, 03 Nov 2022 | US$699.1b | US$154.7b | US$13.0b | 26.2x | 53.8x | 4.5x |
| Sat, 01 Oct 2022 | US$700.3b | US$152.2b | US$17.3b | 23.2x | 40.5x | 4.6x |
| Mon, 29 Aug 2022 | US$782.5b | US$152.3b | US$17.3b | 29.9x | 45.2x | 5.1x |
| Wed, 27 Jul 2022 | US$793.7b | US$148.8b | US$20.2b | 32.4x | 39.3x | 5.3x |
| Fri, 24 Jun 2022 | US$722.6b | US$148.1b | US$20.1b | 29.6x | 35.9x | 4.9x |
| Sun, 22 May 2022 | US$736.5b | US$148.0b | US$20.0b | 31.9x | 36.7x | 5x |
| Tue, 19 Apr 2022 | US$832.4b | US$146.5b | US$25.3b | 34.7x | 32.9x | 5.7x |
| Thu, 17 Mar 2022 | US$835.1b | US$145.3b | US$25.1b | 35.4x | 33.2x | 5.7x |
| Sat, 12 Feb 2022 | US$866.1b | US$143.8b | US$24.9b | 38.2x | 34.8x | 6x |
| Mon, 10 Jan 2022 | US$894.4b | US$138.0b | US$27.3b | 41.7x | 32.7x | 6.5x |
| Wed, 08 Dec 2021 | US$931.3b | US$138.0b | US$27.3b | 42.4x | 34.1x | 6.7x |
| Fri, 05 Nov 2021 | US$1.0t | US$139.5b | US$27.9b | 48.2x | 36.5x | 7.3x |
| Sun, 03 Oct 2021 | US$710.3b | US$105.9b | US$18.6b | 47x | 38.1x | 6.7x |
| Tue, 31 Aug 2021 | US$733.6b | US$105.8b | US$18.7b | 51.9x | 39.3x | 6.9x |
| Wed, 07 Jul 2021 | US$656.3b | US$101.0b | US$17.6b | 39.3x | 37.2x | 6.5x |
| Sat, 10 Apr 2021 | US$569.5b | US$92.3b | US$15.4b | 38.8x | 37x | 6.2x |
| Fri, 01 Jan 2021 | US$553.9b | US$89.0b | US$14.2b | 39x | 39x | 6.2x |
Price to Earnings Ratio
41.6x
Current Industry PE
- Investors are relatively neutral on the American Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 48.2x.
- The 3-year average PS ratio of 5.5x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 5.6% per year over the last three years.
- Revenues for these companies have grown 24% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.15% | |
| Healthcare | 0.82% | |
| Life Sciences | 1.39% | |
| Clinical Research and Equipment | 1.39% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ILMN Illumina | US$114.34 | 20.8% +US$3.1b | -46.5% | PS4.1x | |
| TMO Thermo Fisher Scientific | US$495.34 | 1.1% +US$2.0b | -11.1% | PE32.2x | |
| DHR Danaher | US$222.13 | 1.0% +US$1.6b | -17.1% | PE27.9x | |
| A Agilent Technologies | US$128.88 | 3.1% +US$1.1b | -15.6% | PE30.4x | |
| IQV IQVIA Holdings | US$216.27 | 2.6% +US$1.0b | 2.0% | PE35.4x |
